Barcelona, Spain, November 20, 2014 – Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced results from the Phase 1 dose escalation study of the investigational EZH2 inhibitor EPZ-6438 (referred to as E7438 by Eisai) administered orally as a single agent in patients with advanced solid tumors and B- cell non-Hodgkin lymphomas. These data will be
presented today at 12:10 p.m. CET/6:10 a.m. ET by EORTC Scientific Chair Jean-Charles Soria, M.D., Ph.D., on behalf of study investigator Vincent Ribrag, M.D., both of the Institut Gustave Roussy, at the 26th Annual EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. The slides will be posted to the Epizyme website, www.epizyme.com, before the Company’s conference call. [Read More]